ClinicalTrials.gg
CompletedNCT01418352Updated Oct 7, 2021Results posted

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

A Phase 3 interventional study of Aripiprazole and Placebo in Tourette's Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 35 sites in 5 countries. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-07.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.

Enrollment
6th of 10
83 · median 97
Started
2011
with 2 others
Phase 3
7 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
6 of 10
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 10 studies testing aripiprazole in Tourette Syndrome, this one is the 6th largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 4th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing aripiprazole in Tourette Syndrome as a file.
02

Study summary

The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.

03

Conditions studied

  • Tourette's Disorder

Keywords

  • Tourette's Disorder
  • Tic disorders
04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 7 to 17 year old with , fourth edition -text revision (DSM-IV-TR) diagnostic criteria for Tourette's disorder (TD), confirmed by the kiddie schedule for affective disorders and schizophrenia - present and lifetime version (K-SADS-PL), including the Diagnostic Supplement 5
  • Has a total tic score (TTS) ≥20 on the yale global tic severity scale (YGTSS) at Screening and Baseline
  • Presenting tic symptoms cause impairment in the participant's normal routines, which include academic achievement, occupational functioning, social activities, and/or relationships
  • Females of must have a negative pregnancy test, must be practicing acceptable double-barrier methods of , and must not be pregnant or lactating.
  • Written form (ICF) obtained from a legally acceptable representative \& informed assent at Screening as applicable by study center's Institutional review board/independent ethics committee (IRB/IEC)
  • The participant, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Clinical presentation and/or history, consistent with another neurologic condition that may have accompanying abnormal movements.
  • History of schizophrenia, bipolar disorder, or other psychotic disorder.
  • Participant receiving psychostimulants for treatment of attention-deficit disorder/Attention-deficit hyperactivity disorder (ADD/ADHD) and who have developed and/or had exacerbations of tic disorder after initiation of stimulant treatment.
  • Currently meets criteria for a primary mood disorder.
  • Severe obsessive-compulsive disorder (OCD), per children's yale-brown obsessive compulsive scale (CY-BOCS) score >16.
  • Taken aripiprazole within 30 days of the Screening visit.
  • Received any agent in a clinical trial within 30 days prior to Screening or who were randomized into a clinical trial with Once-weekly aripiprazole at any time.
  • History of neuroleptic malignant syndrome.
  • Sexually active participants not using 2 approved methods of ; breastfeeding or pregnant.
  • Risk of committing suicide
  • Bodyweight lower than 16 kg
  • Taken neuroleptic or antiparkinson drugs \<14 days prior to randomization.
  • Requiring cognitive-behavioral therapy (CBT) for TD during study.
  • Participant meets DSM-IV-TR criteria for any significant psychoactive substance use disorder within the past 3 months.
  • Positive drug screen
  • Participant requires medications not allowed per protocol
  • Use of CYP2D6 and inhibitors or CYP3A4 inducers within 14 days prior to dosing and for duration of study.
  • Inability to swallow tablets or tolerate oral medication
  • Abnormal laboratory test results, vital signs and (ECG) results
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Placebo comparator
    Matching Placebo

    Participants received aripiprazole matching placebo, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.

    Drug: Placebo

  • Experimental
    Aripiprazole 52.5 mg

    Participants received aripiprazole 52.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.

    Drug: Aripiprazole

  • Experimental
    Aripiprazole 77.5 mg

    Participants received aripiprazole 77.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.

    Drug: Aripiprazole

  • Experimental
    Aripiprazole 110 mg

    Participants received aripiprazole 110 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.

    Drug: Aripiprazole

Interventions

  • Aripiprazole tablets once weekly for 8 weeks.

    Also known as: ABILIFY

  • DrugPlacebo

    Aripiprazole matching-placebo once-weekly for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score

    The YGTSS is a semi-structured clinical interview designed to measure the tic severity. This scale consisted of a tic inventory, with 5 separate rating scales to rate the severity of symptoms, and an impairment ranking. Ratings were made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics, each including number, frequency, intensity, complexity, and interference. The YGTSS TTS was the summation of the severity scores of motor and vocal tics. The total tic score (TTS) ranged from 0 (none) to 50 (severe) with higher score represent more severe symptoms (greater reduction from baseline for greater improvement).

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Mean Change From Baseline in Clinical Global Impressions Scale for Tourette's Syndrome (CGI-TS) Score

    The severity of illness and efficacy of study medication for each participant were rated using the CGI-TS scale. The study physician rated the participants total improvement whether or not it is due to study treatment. All responses were compared to the participants condition at Baseline (Day 0). Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 8

  2. Mean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score at Week 8

    The GTS-QOL is a disease-specific patient-reported scale for the measurement of health-related quality of life in participants with Tourette's Disorder, taking into account the complexity of the clinical picture of the disease. The questionnaire consists of a 27-item Tourette's Disorder-specific scale with 4 subscales (psychological, physical, obsessional, and cognitive). The GTS-QOL total score ranged from 0 (extremely dissatisfied with life) and 100 (extremely satisfied with life). A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 8

07

Results

Posted Oct 7, 2021
Limitations and caveats
Limitations of the trial such as small numbers of subjects analyzed or technical problems leading to unreliable data.

Participant flow

A total of 105 participants were screened and 83 were randomized to the treatment. The randomized participants were recruited at 38 sites in the following 5 countries: Bulgaria, Germany, Romania, Ukraine, and the US.

Participant flow — Overall Study
MilestoneAripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching Placebo
Started20212121
Completed17171618
Not completed3453
Withdrew: Lost to follow-up2000
Withdrew: Adverse event0100
Withdrew: Sponsor discontinued trial site0222
Withdrew: Subject withdrew consent0121
Withdrew: Protocol deviation0010
Withdrew: Lack of efficacy as determined by the investigator1000

Outcome measures

PrimaryMean Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score

The YGTSS is a semi-structured clinical interview designed to measure the tic severity. This scale consisted of a tic inventory, with 5 separate rating scales to rate the severity of symptoms, and an impairment ranking. Ratings were made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics, each including number, frequency, intensity, complexity, and interference. The YGTSS TTS was the summation of the severity scores of motor and vocal tics. The total tic score (TTS) ranged from 0 (none) to 50 (severe) with higher score represent more severe symptoms (greater reduction from baseline for greater improvement).

Time frame:
Baseline and Week 8
Reported as:
Mean · score on scale
Mean Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score
score on scaleAripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching Placebo
Mean Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score-8.2 ± 4.8-9.9 ± 6.7-14.5 ± 7.7-9.6 ± 7.5
SecondaryMean Change From Baseline in Clinical Global Impressions Scale for Tourette's Syndrome (CGI-TS) Score

The severity of illness and efficacy of study medication for each participant were rated using the CGI-TS scale. The study physician rated the participants total improvement whether or not it is due to study treatment. All responses were compared to the participants condition at Baseline (Day 0). Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 8
Reported as:
Mean · score on scale
Mean Change From Baseline in Clinical Global Impressions Scale for Tourette's Syndrome (CGI-TS) Score
score on scaleAripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching Placebo
Mean Change From Baseline in Clinical Global Impressions Scale for Tourette's Syndrome (CGI-TS) Score-0.9 ± 0.6-1.1 ± 0.9-1.3 ± 1.0-1.0 ± 0.9
SecondaryMean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score at Week 8

The GTS-QOL is a disease-specific patient-reported scale for the measurement of health-related quality of life in participants with Tourette's Disorder, taking into account the complexity of the clinical picture of the disease. The questionnaire consists of a 27-item Tourette's Disorder-specific scale with 4 subscales (psychological, physical, obsessional, and cognitive). The GTS-QOL total score ranged from 0 (extremely dissatisfied with life) and 100 (extremely satisfied with life). A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 8
Reported as:
Mean · score on scale
Mean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score at Week 8
score on scaleAripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching Placebo
Mean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score at Week 88.8 ± 14.13.8 ± 24.413.1 ± 20.913.4 ± 15.9

Adverse events

Collected over From first dose up to 30 days post last dose (Up to approximately 12 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole 52.5 mg0/20 (0%)0/20 (0%)8/20 (40%)
Aripiprazole 77.5 mg0/21 (0%)0/21 (0%)4/21 (19%)
Aripiprazole 110 mg0/21 (0%)0/21 (0%)16/21 (76.2%)
Matching Placebo0/21 (0%)0/21 (0%)4/21 (19%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventAripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching Placebo
HeadacheNervous system disorders2/202/218/212/21
SomnolenceNervous system disorders1/203/216/210/21
FatigueGeneral disorders0/201/214/211/21
NauseaGastrointestinal disorders2/200/213/211/21
DizzinessNervous system disorders2/200/212/210/21
Abdominal PainGastrointestinal disorders1/201/212/210/21
DiarrhoeaGastrointestinal disorders0/200/212/210/21
VomitingGastrointestinal disorders1/201/212/210/21
NasopharyngitisInfections and infestations0/201/212/211/21
Decreased AppetiteMetabolism and nutrition disorders0/200/212/210/21

Baseline characteristics

The Intention-to-Treat (ITT) Sample included participants randomly assigned to the double-blind treatment (regardless of whether or not they were dosed with study drug).

Age, Continuous
Age, Continuous(Years)Aripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching PlaceboTotal
Mean11.5 ± 3.411.7 ± 2.812.5 ± 2.711.8 ± 2.711.9 ± 2.9
Age, Customized
Age, Customized(Participants)Aripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching PlaceboTotal
7 to 12 years1211111448
13 to 17 years81010735
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching PlaceboTotal
Female383620
Male1713181563
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching PlaceboTotal
Hispanic or Latino02125
Not Hispanic or Latino2019201978
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching PlaceboTotal
White1219191969
Black or African American822214
Weight
Weight(Kilogram)Aripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching PlaceboTotal
Mean44.7 ± 16.349.0 ± 16.252.8 ± 19.645.0 ± 12.547.9 ± 16.4
Height
Height(centimeter)Aripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching PlaceboTotal
Mean148.5 ± 19.0151.8 ± 16.5157.5 ± 14.8151.8 ± 14.4152.4 ± 16.3
BMI (Body Mass Index)
BMI (Body Mass Index)(kilogram per meter squared (kg/m^2))Aripiprazole 52.5 mgAripiprazole 77.5 mgAripiprazole 110 mgMatching PlaceboTotal
Mean19.6 ± 3.720.7 ± 3.820.6 ± 4.919.3 ± 3.720.0 ± 4.0

2 further baseline measures are reported on the registry.

08

Study locations

35 sites
  • Dothan, Alabama 36303, United States
  • San Francisco, California 94143, United States
  • Gainesville, Florida 32610, United States
  • Miami, Florida 33126, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30329, United States
  • Chicago, Illinois 60612, United States
  • Omaha, Nebraska 68131, United States
  • Manhasset, New York 11030, United States
  • Cincinnati, Ohio 45229-3039, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Charlottesville, Virginia 22903, United States
  • La Crosse, Wisconsin 54601, United States
  • Ruse, 7004, Bulgaria
  • Sofia, 1431, Bulgaria
  • Varna, 9010, Bulgaria
  • Aachen, 52074, Germany
  • Dresden, 01307, Germany
  • Hannover, 30625, Germany
  • Muenchen, 80336, Germany
  • Ulm, 89075, Germany
  • Bucuresti, 041914, Romania
  • Cluj-Napoca, 400660, Romania
  • Craiova, 200620, Romania
  • Iasi, 700282, Romania
  • Donetsk, 83008, Ukraine
  • Kharkiv, 61068, Ukraine
  • Kharkiv, 61153, Ukraine
  • Kyiv, 01030, Ukraine
  • Kyiv, 03049, Ukraine
  • Kyiv, 04209, Ukraine
  • Lugansk, 91045, Ukraine
  • Poltava, 36006, Ukraine
  • Stepanivka, 73488, Ukraine
  • Vinnytsia, 21005, Ukraine
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/.

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2011 to primary completion in Mar 2014, 31 months.

Results were first posted in Oct 2021, 7 years 6 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2011
First posted
Aug 17, 2011
StartActual
Aug 2, 2011
Primary completionActual
Mar 12, 2014
CompletionActual
Mar 12, 2014
Results delay requested
Mar 25, 2015
Results first posted
Oct 7, 2021
Last update
Oct 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01418352
Responsible party
Sponsor
First posted
Aug 17, 2011
Start date
Aug 2, 2011
Primary completion
Mar 12, 2014
Completion
Mar 12, 2014
Results posted
Oct 7, 2021
Last update
Oct 7, 2021

Study contacts

Eva Kohegyi, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion